166 related articles for article (PubMed ID: 10356583)
21. [Breast cancer genetics. BRCA1 and BRCA2: the main genes for disease predisposition].
Ruiz-Flores P; Calderón-Garcidueñas AL; Barrera-Saldaña HA
Rev Invest Clin; 2001; 53(1):46-64. PubMed ID: 11332051
[TBL] [Abstract][Full Text] [Related]
22. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
23. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
24. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
26. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
27. Genetics and the multidisciplinary breast center.
Peters JA; Rubinstein WS
Surg Oncol Clin N Am; 2000 Apr; 9(2):367-96. PubMed ID: 10757850
[TBL] [Abstract][Full Text] [Related]
28. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
[TBL] [Abstract][Full Text] [Related]
29. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
[TBL] [Abstract][Full Text] [Related]
30. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
31. The glittering prize.
Nat Genet; 1994 Oct; 8(2):105-6. PubMed ID: 7842002
[No Abstract] [Full Text] [Related]
32. Perspectives in the clinical management of BRCA mutations carriers.
Savarese A; Cognetti F
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
[TBL] [Abstract][Full Text] [Related]
33. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
34. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
Lerman C; Hughes C; Croyle RT; Main D; Durham C; Snyder C; Bonney A; Lynch JF; Narod SA; Lynch HT
Prev Med; 2000 Jul; 31(1):75-80. PubMed ID: 10896846
[TBL] [Abstract][Full Text] [Related]
35. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
36. Genetics: predisposition and management.
Legare RD
Clin Obstet Gynecol; 2011 Mar; 54(1):180-90. PubMed ID: 21278518
[No Abstract] [Full Text] [Related]
37. [Prophylactic surgery of mammary and ovarian carcinoma].
Lux MP; Bani MR; Fasching PA; Beckmann MW
Chirurg; 2005 Dec; 76(12):1145-54. PubMed ID: 16237564
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
[No Abstract] [Full Text] [Related]
39. Cancer genetics for the clinician: recommendations on screening for BRCA1 and BRCA2 mutations.
Clark BA
Cleve Clin J Med; 2000 Jun; 67(6):408-15,. PubMed ID: 10860223
[TBL] [Abstract][Full Text] [Related]
40. Lessons learned from genetic testing.
Esserman L; Kaklamani V
JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]